These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25420811)

  • 41. Mycobacterium tuberculosis infection following renal transplantation in Taiwan.
    Chen CH; Lian JD; Cheng CH; Wu MJ; Lee WC; Shu KH
    Transpl Infect Dis; 2006 Sep; 8(3):148-56. PubMed ID: 16913973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.
    Peleg AY; Husain S; Kwak EJ; Silveira FP; Ndirangu M; Tran J; Shutt KA; Shapiro R; Thai N; Abu-Elmagd K; McCurry KR; Marcos A; Paterson DL
    Clin Infect Dis; 2007 Jan; 44(2):204-12. PubMed ID: 17173218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients.
    Pennington CA; Tischer SM; Lee E; Lee S; Sindelar J; Park JM
    Pharmacotherapy; 2015 Aug; 35(8):748-54. PubMed ID: 26234282
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
    Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
    Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rejection after simultaneous pancreas-kidney transplantation.
    Arbogast H; Malaise J; Illner WD; Tarabichi A; Dieterle C; Landgraf R; Land W;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii11-7, ii62. PubMed ID: 15814544
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
    Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
    Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rituximab induction therapy in highly sensitized kidney transplant recipients.
    Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
    Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients.
    Mitwalli AH; Alam A; Al-Wakeel J; Al Suwaida K; Tarif N; Schaar TA; Al Adbha B; Hammad D
    Nephron Clin Pract; 2006; 102(2):c72-80. PubMed ID: 16244496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Opportunistic infections complicating solid organ transplantation with alemtuzumab induction.
    Helfrich M; Ison MG
    Transpl Infect Dis; 2015 Oct; 17(5):627-36. PubMed ID: 26228653
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Infectious complications in HIV-infected kidney transplant recipients.
    Ailioaie O; Arzouk N; Valantin MA; Tourret J; Calin RO; Turinici M; Mircescu G; Barrou B
    Int J STD AIDS; 2018 Mar; 29(4):341-349. PubMed ID: 28862528
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A 20-year experience with nocardiosis in solid organ transplant (SOT) recipients in the Southwestern United States: A single-center study.
    Majeed A; Beatty N; Iftikhar A; Mushtaq A; Fisher J; Gaynor P; Kim JC; Marquez JL; Mora FE; Georgescu A; Zangeneh T
    Transpl Infect Dis; 2018 Aug; 20(4):e12904. PubMed ID: 29668074
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
    Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
    Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors and outcome in BK virus nephropathy in a Hispanic kidney transplant population.
    Pérez-Torres D; Bertrán-Pasarell J; Santiago-Delpín E; González-Ramos M; Medina-Mangual S; Morales-Otero L; González-Caraballo Z
    Transpl Infect Dis; 2010 Feb; 12(1):16-22. PubMed ID: 19804584
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disseminated histoplasmosis in renal transplant recipients.
    Davies SF; Sarosi GA; Peterson PK; Khan M; Howard RJ; Simmons RL; Najarian JS
    Am J Surg; 1979 May; 137(5):686-91. PubMed ID: 378009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disseminated histoplasmosis in a haemodialysis patient on immunosuppression after graft failure.
    Smak Gregoor PJ; van Saase JL; vd Ingh HF; Weimar W; Kramer P
    Nephrol Dial Transplant; 1996 Mar; 11(3):542-4. PubMed ID: 8671831
    [No Abstract]   [Full Text] [Related]  

  • 60. Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS).
    McKinsey DS; Gupta MR; Riddler SA; Driks MR; Smith DL; Kurtin PJ
    Ann Intern Med; 1989 Oct; 111(8):655-9. PubMed ID: 2802421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.